Core Insights - The stock of Yiming Oncology-B (01541) rose over 5%, currently up 5.22% at HKD 11.47, with a trading volume of HKD 40.4765 million [1] Group 1: Nobel Prize Announcement - Three scientists, including Mary E. Blenko, were awarded the 2025 Nobel Prize in Physiology or Medicine for their research on peripheral immune tolerance mechanisms [1] - This innovative research identified the immune system's inhibitory switch, offering transformative therapies for millions suffering from autoimmune diseases and cancer [1] - Regulatory T cells (Treg cells) maintain immune tolerance through the Foxp3 transcription factor, with their dysfunction closely linked to autoimmune diseases and cancer [1] Group 2: Development of Tazlestobart - Yiming Oncology is actively advancing the clinical development of Tazlestobart (IMM27M), a next-generation CTLA-4 antibody [2] - Tazlestobart works by eliminating Treg cells in the tumor microenvironment to exert its anti-tumor effects [2] - The drug enhances ADCC activity through genetic engineering, targeting specific molecules on Treg cells to modulate their function or quantity, thereby boosting immune responses [2]
宜明昂科-B涨超5% Treg细胞疗法备受关注 目前公司正积极推进泰泽苏拜单抗临床开发